tbuckley/cabot-search huggingface dataset:
755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Authors: D. Berton-Rigaud, P. Pautier, D. Lorusso, C. Gennigens, L. Gladieff, A. Kryzhanivska, J. Bowman, C. Tian, M. Cornfeld, T. Van Gorp
Journal: Annals of Oncology (2023)
752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Authors: O. Le Saux, C. Borel, F. Ghiringhelli, F. Bigot, D. Vansteene, R. Chaltiel, S. Cousin, X. Durando, E. Coquan, C. Abdeddaim, E. Jeannot, E. Guerini Rocco, G. Frige, M. Francisco, M. Halladjian, M. Kamal, F. Legrand, M. Jimenez, B. Cabarrou, C. Le Tourneau
Journal: Annals of Oncology (2023)
716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers
Authors: G. Middleton, L. Marshall, L. Billingham, K.D. Duffus, A. Greystoke, L. Carter, M.D. Forster, N. Cook, D. Hargrave, S. Danson, P. Roxburgh, A.D. Beggs, A. Chaturvedi, L. Chesler, A. Sarmiento-Castro, C. Dive, D. Rothwell, J. Gath, S. Halford, M.G. Krebs
Journal: Annals of Oncology (2023)
747MO First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
Authors: I.L. Ray-Coquard, S. Pignata, J-Y. Lee, R.L. Coleman, J. Brown, J-W. Kim, F. Selle, D. Lorusso, M.J. Bermejo-Pérez, P. Pautier, C. Gourley, A. Ayhan, G. Richardson, D. Cibula, L. Yauch, M. Dieterich, V. Krishnan, O. Calas-Zeroug, P. Harter, D.M. Gershenson
Journal: Annals of Oncology (2023)
691P Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Authors: J.H. Strickler, D.R. Camidge, Y. Kuboki, N. Yamamoto, D. Sommerhalder, A. Vasilopoulos, R.R. Li, K. Freise, G. Morrison-Thiele, M.R. Neagu Aristide, J. Bar
Journal: Annals of Oncology (2023)
768P Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Authors: P. Pautier, J-S. Fresnel, B. You, F. Bazan, C. Lebreton, A. Leary, D. Chaltiel
Journal: Annals of Oncology (2023)
702P Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Authors: K.I. Rojas Laimito, M. Vieito Villar, M.Á. Moya Hernández, G. Pretelli, M.J. Lostes Bardaji, O. Saavedra Santa Gadea, A. Hernando Calvo, V. Galvao, A. Oberoi, G. Alonso, I. Braña, J. Ginard Moya, I. Baraibar Argota, C. Saura Manich, E. Muñoz Couselo, T. Macarulla, C. Garcia Duran, J. Carles Galceran, J. Tabernero, E. Garralda
Journal: Annals of Oncology (2023)
762P Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase II clinical study
Authors: B. Xia, W. Jiang, J. Chen, Y. Chen, W. Shan, W. Shen, Y. Tian, Y. Chen, X. Chen, W. Wu, Y. Ma, J. Wang, W. Qi, Z. Wang, X. Li, X. Huang, H. Lin, B. Hong, H. Zhou
Journal: Annals of Oncology (2023)
704P Regional differences in drug-induced lung disease (DILD) caused by anticancer drugs between the US, EU and Japan: A large-scale data-based analysis using the FDA Adverse Event Reporting System (FAERS)
Authors: R. Sadachi, J. Sato, M.O. Okada, Y. Katsuya, T. Koyama, N. Yamamoto
Journal: Annals of Oncology (2023)
754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Authors: R.E. O'Cearbhaill, K.N. Moore, O. Yeku, J.F. Liu, S. Bouberhan, E.P. Hamilton, J.Y. Hou, E. Van Nieuwenhuysen, K. Papadimitriou, S-Y. Yoo, S. Govindraj, J. Brouwer-Visser, M. Peterman, T. Schmidt, B. Barnes, P. Madia, M. Zhu, T.S. Uldrick, E.A. Miller, D. O'Malley
Journal: Annals of Oncology (2023)

Ubamatamab (REGN4018) is a mucin16 (MUC16) x CD3 bispecific antibody. Cemiplimab, an anti-PD-1 antibody, enhanced its activity in preclinical studies. In phase 1 (NCT03564340), ubamatamab monotherapy resulted in an acceptable safety profile and durable responses. We now present ubamatamab combined with cemiplimab dose escalation results. Patients (pts) with recurrent platinum-experienced ovarian cancer (OC) received weekly intravenous (IV) ubamatamab at a dose range of 1–450 mg after initial step-up dosing. Cemiplimab 350 mg IV every 3 weeks was added beginning Day 29–36. Dose escalation initially followed a modified 3+3 design, then Bayesian optimal interval design. Primary endpoints were safety and PK. Secondary endpoints included confirmed objective response rate (ORR), Kaplan-Meier estimated duration of response (DoR) and progression-free survival (PFS) (RECIST 1.1), and CA125 response (GCIG). 35 pts were enrolled, 29 (82.9%) received ≥1 dose of cemiplimab. Median number of prior therapies was 5 (range 1−10). Median duration of ubamatamab and cemiplimab exposure was 11 (range 2−75) and 12 (3−69) weeks, respectively. The most common treatment-emergent adverse events (TEAE) were pain (82.9%) and cytokine release syndrome (68.6%, all Grade [G] 1/2). The most common G≥3 TEAE were anaemia (25.7%), pain (20.0%) and neutropaenia (11.4%, 1 dose-limiting toxicity [DLT], 60 mg). Ubamatamab 1–250 mg weekly with cemiplimab was tolerable. In the highest dose cohort (450 mg), haemophagocytic lymphohistiocytosis (G4, DLT) was observed. Objective responses were observed at ubamatamab doses 10–250 mg (n=25). In 22 of these pts receiving ≥1 dose of cemiplimab, ORR was 18.2% (95% CI: 5.2–40.3), median DoR 8.3 months (4.2–not estimable), CA125 response rate 22.7% (7.8–45.4) and 6-month PFS 47.6% (25.7–66.7). Two pts with target lesion growth (+17%, +31%) before adding cemiplimab to ubamatamab had subsequent partial responses. Ubamatamab PK was not impacted by cemiplimab. In pts with heavily pretreated OC, an acceptable safety profile and durable responses were observed with ubamatamab + cemiplimab. A randomised phase 2 expansion of ubamatamab +/- cemiplimab is ongoing.
700P First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Authors: A. Cooper, V. Andelkovic, K. Wilkinson, V. Ganju, J. Lundy, M. Hong, S. Airey, L.L. Meng, B. Shen, H. Li, L. Yao, M. Zhang, J. Coward
Journal: Annals of Oncology (2023)
765P SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Authors: X. Wu, J. Liu, L. Wang, Z. Lin, J. Wang, C. Wang, B. Kong, Z. Liang, Y. Cheng, H. Wen, G. Lou, Y. Huang, K. Wang, R. An, J. Zhu, H. Zhou, Y. Yue
Journal: Annals of Oncology (2023)
759P Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter study
Authors: J. Wang, P. Jiang, L. Wei, L. Zou, X. Li, C. Wang, X. Sun, L. Ding, X. Yuan, H. Cheng, D. Wu, R. Cai, R. Yin, J. Zhang, H. Qiu, T. Wang, K. Gao, Y. Zhuo, Y. Zhang, F. Zhao
Journal: Annals of Oncology (2023)

Background: H101 has promising efficacy and favorable safety in patients with persistent /recurrence/metastasis (P/R/M) gynecological cancer, but the evidence regarding the effect of H101 on cervical cancer remains rare.Thus, the purpose of this study is to evaluate the efficacy and safety of H101 intra-tumor injection in P/R/M cervical cancer.Methods: This is a prospective, open-label, single-arm study, with an expected sample size of 60.P/R/M cervical cancer patients who had received at least one line of systemic therapy or could not tolerate chemotherapy were eligible.Patients were given H101 intro-tumor injection (0.5-1.5Â10 12 ) viral particles from day 1 to day 5 combined with or without radiotherapy in sequential, 3 weeks for a cycle (1-4 cycles totally).The primary endpoint is local control (LC) and the secondary endpoints include objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events (AEs).This trial was registered at www.clinicaltrials.govwith identifier number NCT 05051696.Results: Between September 2021 to April 2023, 53 patients were enrolled, in which 49 patients (92.45%) completed at least 1 tumor assessment with a median follow-up time of 8 months (95%CI: 7-11months).The LC rate at 3 months was 73.5% (95%CI: 60.7%-86.3%),and the median PFS and OS were currently not reached.The ORR was 69.4% (95%CI: 56%-82.8%),and the disease control rate (DCR) was 81.6% (95%CI: 70.4%-92.9%)by RECIST1.1.The most frequently reported AEs were fever (62.8%), fatigue (32.65%), vomiting (20.41%), bleeding (16.3%), pain (16.3%) and bird-flue like symptoms (16.3%).All frequently occurring AEs were grade 1 or 2. High grade AE was only observed in 3 patients with rectovaginal fistula grade 3. Neither unexpected safety signals nor treatment related death occurred. Conclusions:We present here for the first time that H101 is a strong candidate for virotherapy in P/R/M cervical cancer.These results demonstrate that H101 combined with or without radiotherapy could improve clinical outcomes significantly in patients with P/R/M cervical cancers with acceptable toxicity.Clinical trial identification: NCT05051696.
761P A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification
Authors: J.M. Piulats Rodriguez, I. Palacio Vazquez, J.D. Alarcon, S. Gatius, J.A. Marin Jimenez, M. Gil Martín, A. Márquez Aragonés, M. Santacana, L.M. Manso Sanchez, S. Hernando Polo, N. Ruiz, X. Matias-Guiu, M. Romeo Marin, V. Navarro Garces, P. Barbarroja
Journal: Annals of Oncology (2023)
745MO Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study
Authors: K.N. Moore, A. Philipovskiy, K. Harano, B.I. Rini, K. Sudo, S. Kitano, D.R. Spigel, J. Lin, M. Kundu, A. Bensmaine, Y. Myobatake, E.P. Hamilton
Journal: Annals of Oncology (2023)
686P Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Authors: J. Wu, J. Zhang, Y. Meng, Y. Du, X. Liu, Y. Mu, Y. Zhang, J. Wang, W. Xin, X. Zhu
Journal: Annals of Oncology (2023)
701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Authors: T.A. Yap, S.A. Piha-Paul, D. Karp, E.E. Dumbrava, D.S. Hong, S. Fu, V. Subbiah, A.M. Tsimberidou, J. Rodon, J. Rhudy, C. Valladolid, Y. Yuan, B. Jana, P. Spiliopoulou, L. Randall, A. Poklepovic, K. Sehgal, G.I. Shapiro, R. Said, F. Meric-Bernstam
Journal: Annals of Oncology (2023)
774P CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Authors: F. Blanc-Durand, N.Y.L. Ngoi, E. Rouleau, S.Y.R. Ang, P. Pautier, J. Michels, K. Ouali, C. Genestie, S. Cotteret, Y.W. Lim, S.E. Lim, D. Lim, S.T. Wijaya, A.C. Seong, A. Leary, D.S. Tan
Journal: Annals of Oncology (2023)
722TiP CLAUDIO-01: A multicentric phase I/II trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care (SoC) in patients with gastric, gastroesophageal junction(GEJ), and pancreatic adenocarcinoma
Authors: R. Obermannova, A. Hollebecque, T. Macarulla, R. Alvarez Gallego, E. Van Cutsem, R.S. Conde, A-R. Hanauske, V. Boura, J. Tabernero
Journal: Annals of Oncology (2023)
750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Authors: B.M. Slomovitz, N. Raaschou-Jensen, R.L. Coleman, L. Gilbert, M.A. Powell, D. Cibula, S. Ghamande, L. Zavallone, A.A. Mendivil, B. Ataseven, D. Black, M. Wymenga, C. Billingsley, L.J. Willmott, C. McCourt, I. Podzielinski, O. Doehring, J. Garside, T.J. Herzog, M.R. Mirza
Journal: Annals of Oncology (2023)
763P Penpulimab + anlotinib plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, phase II study (ALTN-AK105-II-06)
Authors: Q. Xu, J. Liu, L. Li, Y. Lin, Y. Chen, Y. Song, L. Luo
Journal: Annals of Oncology (2023)
692P First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Authors: W.W. Ma, D. Orr, C.A. Perez, Y.R. Murciano-Goroff, E.P. Hamilton, Y. Zhao, C. Anders, G.P. Adams, C. Reddick, H. Wroe McClintock, E. Bayever, A.W. Tolcher
Journal: Annals of Oncology (2023)
717TiP An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
Authors: M.A. Dudek, Z. Zasłona, R. Błaszczyk, M.M. Grzybowski, T. Rejczak, A. Cabaj, P. Dera, K. Lisiecki, P. Iwanowski, T. Charitos, S. Fung
Journal: Annals of Oncology (2023)
719TiP A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
Authors: M. Moschetta, T. Doi, Y. Kuboki, R. Sundar, H. Möbitz, I. Jaco, M. Cortes Cros, S. Ferretti, D. Jankovic, M. Thérier, G. Clementi, Y. Li, R. De Kanter, C. Quadt
Journal: Annals of Oncology (2023)
773P Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Authors: C. Lazaro, E. Jantus Lewintre, S. Zazo, S. Pérez, N. Carvajal Garcia, D. Azuara, M. González Acosta, M. Varela, S. Torres-Martínez, S. Gallach Garcia, M. Colomar, M. Sanchez Ares, R. Perez-Becerra, J.R. Antunez, M. Orellana, M. Lencina, I. Abdulkader Nallib, C.J.C. Camps Herrero, X. Matias-Guiu, F. Rojo
Journal: Annals of Oncology (2023)
742MO Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer
Authors: M. de Bruyn, A.L. Eerkens, K. Brummel, A. Vledder, S.T. Paijens, M. Requesens, D. Loiero, N. van Rooij, A. Plat, P. Klok, F-J. Haan, D.N. Church, R. Wardenaar, F. Foijer, V.H. Koelzer, T. Bosse, J. Bart, M. Jalving, A.K.L. Reyners, H.W. Nijman
Journal: Annals of Oncology (2023)
743MO Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, multicenter phase II study
Authors: N. Liu, Z. Yang, D. Tang, H. Lou, K. Zhang, H. Cao, D. Zou, X. Zhang, S. Xue, X. Kang, D. Wang
Journal: Annals of Oncology (2023)
715TiP ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Authors: Y. Wang, Q. Sheng, T. Ji, J. Liang, N. Schomer, J. Fu, T. Zhang, W. Xiong, D. Cheng, Z. Liu, Q. Ding, F. Li, Y. Chen, G. Berk
Journal: Annals of Oncology (2023)
746MO Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)
Authors: J-M. Lee, A. Miller, P. Rose, M. AlHilli, C. Washington, V. John, C. Shah, K. Matsuo, J. Siedel, D.S. Miller, J. Chan, E. Hopp, E.C. Kohn, K.N. Moore, J.F. Liu
Journal: Annals of Oncology (2023)
758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Authors: M. Saint-Ghislain, C. Abdeddaim, R. Chaltiel, S. Cousin, C.A. Gomez-Roca, C. Borel, F. Ghiringhelli, D. Vansteene, F. Bigot, E. Jeannot, E. Guerini Rocco, G. Frige, L. Mazzarella, M. Francisco, F. Legrand, M. Jimenez, M. Halladjian, M. Kamal, B. Cabarrou, C. Le Tourneau
Journal: Annals of Oncology (2023)
777P Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Authors: D. Shintani, M. Hanaoka, Y. Kaneda, A. Ogasawara, M. Yano, T. Katoh, M. Yasuda, M. Nagata, K. Hasegawa
Journal: Annals of Oncology (2023)

Cadherin-6 (CDH6) is a transmembrane glycoprotein, whose aberrant expression has been reported in several human carcinomas. Raludotatug deruxtecan(R-DXd) is an antibody-drug conjugate (ADC) targeting CDH6 with a topoisomerase I inhibitor (DXd) as a payload which is being developed for several malignancies, including epithelial ovarian cancer (EOC). Our aim was to understand the clinical significance of CDH6 expression in EOC and investigate the efficacy and specificity of R-DXd in EOC using patient-derived cell (PDC) models. We performed immunohistochemical staining (IHC) for CDH6 in 232 EOC surgical samples and 23 ascites cell blocks. CDH6 IHC was scored for intensity and percent tumor cell staining. A score greater than or equal to 1+ intensity in ≥10% of tumor cells was defined as positive. The in vitro cytotoxicity and specificity of DS-6000a were evaluated in PDC models of EOC in 3-dimensinal (3D) cell culture using a luminescence-based 3D cell viability assay. A total of 117 (64.6%) of 181 patients tested positive for CDH6 expression in archival specimens from primary surgery. CDH6 expression was more frequently observed in high-grade serous carcinomas (89.0%, p < 0.0001). CDH6-positive patients showed shorter overall survival than CDH6-negative patients (p = 0.0006). 38 of the 51 (74.5%) tumors and 15 of the 23 (65.2%) ascites cells specimens from patients with recurrent disease tested positive for CDH6, respectively. Recurrent tumors had higher CDH6 scores than tumors at primary surgery, using 24 paired samples (p = 0.0039). R-DXd, DXd (free payload), control ADC and anti-CDH6 naked antibody were tested for their cytotoxicity in two CDH6-positive and two CDH6-negative PDC models. R-DXd showed significant cell growth inhibitory effect against both CDH6-positive but not in either CDH6-negative PDC models. DXd demonstrated cytotoxicity in all PDC models, regardless of CDH6 expression, whereas control ADC and anti-CDH6 naked antibody showed no growth inhibitory effects. CDH6 is an attractive target for EOC and R-DXd is a promising agent for the treatment of CDH6-expressing EOC.
693P Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Authors: Y. Shan, R. Liu, G. Song, H. Song, J. Jiang, C. Jia, Y. Chen, X. Yuan, Z. Hou, X. Wang, X. Hou, Y. Shen, C. Hu, H. Wei, Q. Wang, J. Zhu
Journal: Annals of Oncology (2023)
740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Authors: M.R. Mirza, S. Sharma, J. Herrstedt, M.S. Shahin, D. Cibula, E. Fleming, F. Raspagliesi, J. Buscema, L.C. Hanker, R.L. Coleman, I.A. Boere, K. Schneider, L. Gilbert, B.M. Slomovitz, M.G. Teneriello, M.A. Powell, S. Ghosh, S. Stevens, K. Ring, A. Stuckey
Journal: Annals of Oncology (2023)
696P SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Authors: F. Liu, N. Yang, J. Wang, R. Wang, Z. Han, C. Yang, J. Li, Z. Liu, Y. Li, J. Tang, A. Cui, R. Xu
Journal: Annals of Oncology (2023)
749P Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Authors: G. Valabrega, M.A. Powell, S. Hietanen, E.M. Miller, Z. Novák, R. Holloway, D. Denschlag, T. Myers, A.M. Thijs, K. Pennington, L. Gilbert, E. Fleming, L. Copeland, R. Gogoi, I. Podzielinski, N. Cloven, O. Meyers, J. Garside, M.R. Mirza, D. Black
Journal: Annals of Oncology (2023)
697P Open-label, phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab
Authors: M. Gutierrez, R. Jamal, N. Yamamoto, T. Doi, M. Elgadi, J.L. Ferrada, S.M. Wojciekowski, M.R. Patel
Journal: Annals of Oncology (2023)
694P Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Authors: P. Bono, L. Verlingue, M.J. De Miguel Luken, A. Pasanen, D. Robbrecht, T. Skyttä, S.M.E. Iivanainen, S. Shetty, Y.T. Ma, D.M. Graham, S.P. Arora, P.M. Jaakkola, C. Yap, M. Hollmén, J.P. Koivunen, A.R. Minchom
Journal: Annals of Oncology (2023)
769P Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Authors: J. Overbeek, N. Guchelaar, M.I. Mohmaed Ali, P.B. Ottevanger, H. Bloemendal, S. Koolen, R. Mathijssen, I. Boere, P. Hamberg, A. Huitema, G. Sonke, F. Opdam, R. Ter Heine, N. Van Erp
Journal: Annals of Oncology (2023)
687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Authors: J.S. de Bono, S. Lord, C. Yap, S. Miranda, G.J. Veal, K. Chandran, A. Paschalis, C. Peron, J. Rekowski, B. Gurel, D. Paisley, L. McGuigan, P.J. Ingram, K.Y. Kwek, G. Halbert, N.B. Westwood, A.E. Griffin, L. Kostaras, J.D. Boyd-Kirkup, H.S. Walter
Journal: Annals of Oncology (2023)
689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Authors: O. Marathe, Y. Cheng, A.I. Spira, E.P. Hamilton, M.M. Rubinstein, X. Dong, L. Li, D. Lv, J. Shi, N. Gabrail, H. Amin, C. Wu, Z. Zhu, Y. Qiu, V. Gu, X. Qiu, R. Shi, L. Liu, P. Miao, N.T. Ueno
Journal: Annals of Oncology (2023)
708P Final clinical outcomes of nationwide precision oncology pilot study; KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS) KCSG AL-20-05
Authors: T-Y. Kim, S.Y. Kim, J.H. Kim, H.A. Jung, Y.J. Choi, I.G. Hwang, Y. Cha, G-W. Lee, Y-G. Lee, T.M. Kim, S-H. Lee, S. Lee, H. Yun, Y-L. Choi, S. Yoon, S-W. Han, T-Y. Kim, T.W. Kim, D.Y. Zang, J.H. Kang
Journal: Annals of Oncology (2023)
770P Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Authors: M.J. Rubio Perez, A. Manzano Fernández, L.M. De Sande González, P. Estevez Garcia, M.D.M. Gordon Santiago, D. Soto de Prado, B.A. Hernando Fernandez, E.M. Guerra Alia, A. Carbo Bague, I. Romero, M. Corbellas Aparicio, A. Gonzalez-Haba Martinez, C.E. Robles Barraza, J. Martinez-Garcia, A. Gonzalez Martin
Journal: Annals of Oncology (2023)
753P IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Authors: L. Wu, J. Wang, L. Wang, W. Lu, K. Wang, A. Lin, N. Li, L. Li, N. Su, S. Xie, J. Jiang
Journal: Annals of Oncology (2023)
713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
Authors: I. Dagogo-Jack, A. Dowlati, R. Guo, M.M. Awad, A. Swalduz, E. Calvo, V. Moreno Garcia, A.A. Adjei, P. Lorusso, S. Punekar, T.A. Leal, T.A. Yap, A. Italiano, W. Novotny, C. Tankersley, S. Rowe, G. Paris, W. Sun, A.I. Spira, B. Besse
Journal: Annals of Oncology (2023)